Author

Ashlee K. Clark

Monash UniversityORCID 0000-0002-0851-9224Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Gail Petuna RisbridgeriD· 2 shared Mitchell G. LawrenceiD· 2 shared Renea A. TayloriD· 2 shared Adrià ClosaiD· 1 shared Alisee HugloiD· 1 shared Amee J. GeorgeiD· 1 shared Andrew BakshiiD· 1 shared Andrew RyaniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Gail Petuna RisbridgerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyMolecular OncologyPeer-reviewedJul 24, 2025

Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptors

Rosalía Quezada Urban, Shivakumar Keerthikumar, Ashlee K. Clark…·David L. Goode

This study uses single-cell RNA sequencing to show that focal neuroendocrine differentiation (Focal NED) in prostate cancer is transcriptionally distinct, characterized by androgen receptor expression and unique transcriptional sub-populations.

3 citations

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 19, 2025

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

Rita Ferreira, Katherine M. Hannan, Kostya I. Panov…·Nadine Hein

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

6 citations

humanexperimental assay

𝕏 PostBluesky